The Clinical Development of Lurtotecan

[1]  D. Emerson,et al.  Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice , 2001, Anti-cancer drugs.

[2]  R. Paridaens,et al.  Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  D. Baccanari,et al.  Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  U. Massing,et al.  Liposomal formulations of anticancer drugs: selectivity and effectiveness. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[5]  P. Sinko,et al.  The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s). , 2000, Anticancer research.

[6]  Y. Pommier,et al.  Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. , 1999, Cancer research.

[7]  S. Hecht,et al.  Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. , 1999, Biochemistry.

[8]  L. Grochow,et al.  Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Hainsworth,et al.  A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma , 1999, Cancer.

[10]  A. Rolland,et al.  Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. , 1998, Journal of medicinal chemistry.

[11]  P. Uster,et al.  Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  L. Paz-Ares,et al.  A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. , 1998, British Journal of Cancer.

[13]  M. Wall,et al.  Camptothecin and taxol: Discovery to clinic , 1998, Medicinal research reviews.

[14]  D. V. Von Hoff,et al.  Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  T. Uchiumi,et al.  A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. , 1997, Cancer research.

[16]  P. D'Arpa,et al.  Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin* , 1997, The Journal of Biological Chemistry.

[17]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. D'Arpa,et al.  Mechanism of Action of Camptothecin , 1996, Annals of the New York Academy of Sciences.

[19]  J. Murren,et al.  Camptothecin Resistance Related to Drug‐induced Down‐Regulation of Topoisomerase I and to Steps Occurring after the Formation of Protein‐linked DNA Breaks a , 1996, Annals of the New York Academy of Sciences.

[20]  J. Verweij,et al.  Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. , 1996, British Journal of Cancer.

[21]  K. Kohn,et al.  Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. , 1995, Biochemistry.

[22]  D. Emerson,et al.  In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. , 1995, Cancer research.

[23]  T. Burke,et al.  Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. , 1994, Biochemistry.

[24]  T. Burke,et al.  Differential interactions of camptothecin lactone and carboxylate forms with human blood components. , 1994, Biochemistry.

[25]  Y. Pommier,et al.  Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. , 1994, Journal of the National Cancer Institute.

[26]  T. Burke,et al.  Liposomal stabilization of camptothecin's lactone ring , 1992 .

[27]  Y. Pommier,et al.  Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. , 1989, Cancer research.

[28]  K. Kohn,et al.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.

[29]  R. Hertzberg,et al.  Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. , 1989, Journal of medicinal chemistry.

[30]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[31]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[32]  P. D'Arpa,et al.  Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines. , 1998, Oncology research.

[33]  J. Verweij,et al.  The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. , 1997, British Journal of Cancer.

[34]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  L. Liu,et al.  A model for tumor cell killing by topoisomerase poisons. , 1990, Cancer cells.